Solu Therapeutics is a biotechnology company dedicated to developing next-generation therapeutics to eliminate disease-driving cells in cancer, immunology and other therapeutic areas. The company’s proprietary CyTAC (Cytotoxicity Targeting Chimera) and TicTAC (Therapeutic Index Control Targeting Chimera) platforms enable the development of innovative medicines that combine the target-binding capability of small molecules with the therapeutic power of biologics.

Solu Therapeutics INC
TAP Partner
Boston, Massachusetts
United States
Project Title
A phase 1 study of STX-0712, a CCR2-CyTAC monocyte depletor, in patients with CMML
Program
Therapy Acceleration Program